CureVac’s Covid Vaccine Performed Badly in Trial, In Part Due to Variants
A preliminary analysis estimated that CureVac’s mRNA vaccine had an efficacy of just 47 percent. “This is pretty devastating for them,” one expert said.
View original article
Contributor: Carl Zimmer
